Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2020
Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus GuidelinesSimron Singh, Emily K Bergsland, Cynthia M Card, et al.
International Journal of Radiation Oncology, Biology, Physics|January 28, 2023
Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution ExperienceDaniel E Oliver, Jose M Laborde, Deepinder P Singh, et al.
Endocrine Connections|September 2, 2016
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementKjell Oberg, Eric Krenning, Anders Sundin, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Consensus on molecular imaging and theranostics in neuroendocrine neoplasmsValentina Ambrosini, Jolanta Kunikowska, Eric Baudin, et al.
Lancet (London, England)|July 2, 2026
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trialThomas Walter, Henning Jann, Catherine Ansquer, et al.
The New England Journal of Medicine|January 12, 2017
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Ghassan El-Haddad, Edward Wolin, et al.
The Lancet. Oncology|July 3, 2026
Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS)Christophe M Deroose, Hannes Leupe, Rodney J Hicks, et al.
ERJ Open Research|January 21, 2026
Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasiaMarissa O'Callaghan, Sarah H Forde, Alessandro N Franciosi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 12